FOR 6219
Alternative Names: FOR-6219; OG-6219Latest Information Update: 13 Jun 2025
At a glance
- Originator Hormos Medical; Solvay Pharmaceuticals B.V.; University of Turku
- Developer Organon
- Class Small molecules
- Mechanism of Action Estradiol dehydrogenase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Endometriosis
Most Recent Events
- 28 May 2025 Organon completes a phase-II clinical trials in Endometriosis (In adults) in Latvia, Sweden, Poland, Italy, France, Hungary, Germany, Czech Republic, Czech Republic, Bulgaria, Belgium, USA (PO) (NCT05560646)
- 28 Nov 2023 No recent reports of development identified for phase-I development in Endometriosis(In volunteers) in United Kingdom (PO)
- 14 Oct 2022 Phase-II clinical trials in Endometriosis in USA (PO) (NCT05560646)